Protein kinase inhibitors: contributions from structure to clinical compounds.
about
Phosphoproteomics reveals malaria parasite Protein Kinase G as a signalling hub regulating egress and invasion.Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-MetDiscovery of a Potential Allosteric Ligand Binding Site in CDK2A Novel Mode of Protein Kinase Inhibition Exploiting Hydrophobic Motifs of Autoinhibited Kinases: DISCOVERY OF ATP-INDEPENDENT INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTORCrystal Structures of Two Aminoglycoside Kinases Bound with a Eukaryotic Protein Kinase InhibitorMolecular Mechanism of Selectivity among G Protein-Coupled Receptor Kinase 2 InhibitorsFluorophore Labeled Kinase Detects Ligands That Bind within the MAPK Insert of p38α KinaseParoxetine Is a Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial ContractilityA Novel Approach to the Discovery of Small-Molecule Ligands of CDK2The active conformation of human glucokinase is not altered by allosteric activatorsDevelopment of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent KinasesAminoglycoside 2′′-Phosphotransferase IIIa (APH(2′′)-IIIa) Prefers GTP over ATPCyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of BromodomainsMolecular Mechanism for Inhibition of G Protein-Coupled Receptor Kinase 2 by a Selective RNA AptamerA genetically encoded 19F NMR probe for tyrosine phosphorylationPyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsStructure of the phosphotransferase domain of the bifunctional aminoglycoside-resistance enzyme AAC(6′)-Ie-APH(2′′)-IaMechanisms of drug resistance in kinases.Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsMalaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulationBinding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurementsSynthesis and antiangiogenic activity of N-alkylated levamisole derivativesLapatinib-binding protein kinases in the African trypanosome: identification of cellular targets for kinase-directed chemical scaffoldsA comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determinationLenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell linesComputational insights for the discovery of non-ATP competitive inhibitors of MAP kinasesNew chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugsVenus kinase receptors control reproduction in the platyhelminth parasite Schistosoma mansoniPhotocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MSA theoretical entropy score as a single value to express inhibitor selectivity.Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesTyrosine kinases in inflammatory dermatologic disease.ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.c-Kit signaling determines neointimal hyperplasia in arteriovenous fistulaePolyphony: superposition independent methods for ensemble-based drug discovery.
P2860
Q27230115-E55A6026-0A32-4477-8598-57AFD726CFBEQ27666642-3335CDF4-1E58-4CCA-9DEE-8E2B54738BC2Q27666837-034832C9-23B3-4AF1-A8CE-2A9E75619E2EQ27667388-E3CC2A42-0509-4F24-8B4E-AAAD6DB5CA14Q27667856-8C32CF64-E4BA-4D22-BCDC-90E604536CD6Q27667904-9D43F15B-7CA9-4015-A4B8-F5DE4C07257BQ27670655-38F7D7C7-F2B0-4FBE-B7F4-1EB946C536FCQ27671474-944EECA7-A431-4625-AD46-575DA71B6ACBQ27671549-5D1FD831-F4DF-43B8-B0CC-DAFFC6562428Q27675665-158FB496-0ADB-4424-8176-29C859EB69FAQ27677453-F4CA9FA6-07AF-4338-8140-E49803C420F6Q27677499-45F5F8FE-3E2B-493D-9581-79338D423A5EQ27679876-CEBC8263-E6F7-4BA6-BBA4-DE3423CD7E91Q27681349-5EE93DBB-7CC2-476A-A604-728457AFDA65Q27684095-D6DEE265-659F-4D37-A481-083E430DF8FEQ27684109-B986795E-EA4E-4B09-9FC9-388F22542FC8Q27684260-B7373FA5-D7E5-40DD-A212-48B718DDEB94Q27692567-4106A926-878D-4DD1-9B1E-9F754B049983Q27693185-5B0DFF02-4802-4A74-A340-07BC920FDDCFQ27973595-25EA3CE7-0235-4491-9126-4F977AD155CAQ28475132-DA6B1F4C-4F44-44A1-9CC9-8A29A7BA3F84Q28483795-C8865876-F928-48AC-9B26-38E5F3C91549Q28486270-7CE9DA23-97F9-4486-BDAE-855E6514C6BFQ28539535-A8A091C4-E005-48E5-8FF3-669F8768B451Q30249385-BADFF5BD-32B1-46A1-A231-64B7C82B4489Q31159325-62CB3E9A-BC5C-46FA-9056-9A0E9C1C5CE6Q33593739-BF0ECC93-460A-4BC7-A129-456AFBF12461Q33622982-C20463CD-69BB-4E62-99A7-91A05B444738Q33686019-EE0C30C2-17D1-41FA-9277-C861955ED208Q33699182-0BF59047-5838-469F-B2AB-185D006AC1AEQ33870615-EE8FCB45-6E48-43BA-BF50-FBD99D9CF6F2Q34004544-BFBC29F5-80C7-470B-8815-ED63A50D67E8Q34077272-6218A749-0672-4AEC-A222-1B76F72CEB84Q34088265-72330766-6628-4F18-B4AF-0A87B29E286CQ34122676-1EBDB212-CF84-4AD3-A722-DE5CD2F54501Q34158454-5042DD86-E60D-4432-B9E2-ACBFB9E56210Q34166503-57994174-2CEE-433D-9331-99C47B97AAADQ34333456-E3346A90-164A-4D0A-8B03-D64DE4B4CB45Q34439804-549FBFC5-1CC9-43A4-979E-69B7D0DD2D7EQ34668264-EFEBB811-DA89-40FF-859D-3A5B94044CDC
P2860
Protein kinase inhibitors: contributions from structure to clinical compounds.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protein kinase inhibitors: contributions from structure to clinical compounds.
@en
Protein kinase inhibitors: contributions from structure to clinical compounds.
@nl
type
label
Protein kinase inhibitors: contributions from structure to clinical compounds.
@en
Protein kinase inhibitors: contributions from structure to clinical compounds.
@nl
prefLabel
Protein kinase inhibitors: contributions from structure to clinical compounds.
@en
Protein kinase inhibitors: contributions from structure to clinical compounds.
@nl
P2860
P1476
Protein kinase inhibitors: contributions from structure to clinical compounds.
@en
P2093
Louise N Johnson
P2860
P356
10.1017/S0033583508004745
P577
2009-02-01T00:00:00Z